Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 31

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 31
---
SG initiatives and metrics from across the company that are aligned not only with 20

our values and our culture, but also with the United Nations Sustainable Development Goals and the standards for the Biotechnology and Pharmaceuticals industry set by the Sustainability Accounting Standards Board, now part of the International Financial Reporting Standards (IFRS). Our 2025 ESG Report is available on our website, www.agios.com, under the “Corporate Governance” section. The contents of the ESG Report are not deemed to be part of this proxy statement or incorporated by reference herein.

Our ESG program is centered around our commitments to the patients we serve, our employees, our communities and world, and business ethics and values.

Our Commitment to Patients

Advancing Science

We are focused on making a difference for rare disease patients by discovering, developing, and delivering innovative therapies. Our pioneering research in pyruvate kinase, or PK, activation led to the first approved therapy for PK deficiency, a rare, debilitating, lifelong blood disorder, and has also driven the development of a robust clinical and preclinical pipeline. This pipeline spans late-, mid- and early-stage programs targeting several rare diseases, including thalassemia, sickle cell disease, or SCD, lower-risk myelodysplastic syndromes, or MDS, phenylketonuria and polycythemia vera.

Improving Care for Underserved Communities

In addition to developing the first approved therapy for PK deficiency, we have also supported this patient community holistically. We have made significant progress in understanding the burden of PK deficiency by funding a natural history study and establishing the first global patient registry. Additionally, we have developed educational resources for physicians and patients, and partnered with patient advocacy groups to create the first international PK deficiency patient advisory council — a multidisciplinary team including patients, caregivers, advocates and clinicians.

We have taken a similar approach to supporting the thalassemia community. There are currently no approved treatment options for those with alpha-thalassemia, and treatment options are limited for those with beta-thalassemia. Our global thalassemia clinical development programincludes patients across the full range of thalassemia subtypes, including both alpha- and beta-thalassemia as well as transfusion-dependent and non-transfusion-dependent thalassemia. Based on the positive results from the ENERGIZE and ENERGIZE-T phase 3 studies, we filed regulatory applications for PYRUKYND